AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
Enhertu's potential approval as a post-neoadjuvant treatment for HER2-positive early breast cancer could significantly improve patient outcomes by reducing recurrence risk.
AstraZeneca's Enhertu receives US FDA Priority Review for HER2-positive early breast cancer post-neoadjuvant treatment, potentially establishing a new standard of care.
AstraZeneca and Daiichi Sankyo's Enhertu has been granted Priority Review by the US FDA for treating adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment. This is based on the DESTINY-Breast05 Phase III trial, where Enhertu showed a 53% reduction in the risk of invasive disease recurrence or death compared to trastuzumab emtansine (T-DM1). The FDA's decision is expected in the third quarter of 2026. If approved, Enhertu could become a new standard of care in this setting.
Enhertu's potential approval as a post-neoadjuvant treatment for HER2-positive early breast cancer could significantly improve patient outcomes by reducing recurrence risk. This would establish a new standard of care, addressing a critical unmet need for patients with residual disease after initial therapy and potentially preventing progression to metastatic disease.
Where this signal fits in the broader landscape.
AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-granted-priority-review-in-the-us-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In